Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Tyverb

Tyverb 250 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7

HOS-208921 · Präparat HOS-154213

In healthy volunteers receiving carbamazepine, a CYP3A4 inducer, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure to lapatinib was decreased approximately 72%. Co-administration of Tyverb with known inducers of CYP3A4 (e.g. rifampicin, rifabutin, carbamazepine, phenytoin or Hypericum perforatum [St John’s Wort]) should be avoided.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): carbamazepine (HOS-085618) rifabutin (HOS-086262) phenytoin (HOS-084531)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-01-06T15:40:00Z · SHA-256 cc5bd96641c0b3f4003ec76839196782d898a5b2fc432b1735c84b65f7171b92 · Passage b4008efad1bbd9a4e7001a9512a3c79a519540cfb36514379d30d2658e254f23 · Zeichen 689–1059 im Abschnitt

Wechselwirkungen · Celsentri

CELSENTRI 150 mg film-coated tablets CELSENTRI 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11–12

HOS-118468 · Präparat HOS-094825

11 Rifabutin + PI Not studied. Rifabutin is considered CELSENTRI dose should to be a weaker inducer than be decreased to 150 mg rifampicin. When combining twice daily when rifabutin with protease inhibitors that co-administered with are potent inhibitors of CYP3A4 a rifabutin and a PI (except net inhibitory effect on maraviroc is tipranavir/ritonavir where expected. the dose should be 300 mg twice daily). See also section 4.4.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) rifabutin (HOS-086262) ritonavir (HOS-084521) tipranavir (HOS-086184)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-01-12T15:51:00Z · SHA-256 af7f0c7bbfd6e612d5a885c59ba9795f11ee85b00c3e0504de2a206af5fbec72 · Passage 9ca5523c6be1ced70244c332f06eacfd7a5ca2ca150dce1d0e88a5d8ca00e679 · Zeichen 16349–17154 im Abschnitt

Wechselwirkungen · Celsentri

CELSENTRI 20 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 37–38

HOS-118508 · Präparat HOS-094825

Ritonavir AUC12: ↔ 0.93 Ritonavir Cmax: ↔ 1.02 Ritonavir C12: ↓ 0.74 Etravirine and Not studied. Based on the extent of lopinavir/ritonavir, inhibition by lopinavir/ritonavir, saquinavir/ritonavir or saquinavir/ritonavir or atazanavir/ritonavir atazanavir/ritonavir in the absence of etravirine, an increased exposure is expected. ANTIBIOTICS 37 Sulphamethoxazole/ Maraviroc AUC12: ↔ 1.11 CELSENTRI 300 mg twice Trimethoprim Maraviroc Cmax: ↔ 1.19 daily and sulphamethoxazole/ 800 mg/160 mg BID Sulphamethoxazole/trimethoprim trimethoprim can be (maraviroc 300 mg BID) concentrations not measured, no co-administered without dose effect expected. adjustment. Rifampicin 600 mg QD Maraviroc AUC: ↓ 0.37 CELSENTRI dose should be (maraviroc 100 mg BID) Maraviroc Cmax: ↓ 0.34 increased to 600 mg twice Rifampicin concentrations not daily when co-administered measured, no effect expected. with rifampicin in the absence of a potent CYP3A4 inhibitor. This dose adjustment has not been studied in HIV patients. See also section 4.4. Rifampicin + efavirenz Combination with two inducers has Concomitant use of not been studied. There may be a risk CELSENTRI and rifampicin of suboptimal levels with risk of loss + efavirenz is not of virologic response and resistance recommended. development. Rifabutin + PI Not studied. Rifabutin is considered CELSENTRI dose should be to be a weaker inducer than decreased to 150 mg twice rifampicin. When combining rifabutin daily when co-administered with protease inhibitors that are with rifabutin and a PI potent inhibitors of CYP3A4 a net (except tipranavir/ritonavir inhibitory effect on maraviroc is where the dose should be 300 expected. mg twice daily). See also section 4.4. Concomitant use of CELSENTRI and fosamprenavir/ritonavir is not recommended. Clarithromycin, Not studied, but both are potent CELSENTRI dose should be Telithromycin CYP3A4 inhibitors and would be decreased to 150 mg twice expected to increase maraviroc daily when co-administered concentrations. with clarithromycin and telithromycin. ANTICONVULSANTS Carbamezepine, Not studied, but these are potent CELSENTRI dose should be Phenobarbital, CYP3A4 inducers and would be increased to 600 mg twice Phenytoin expected to decrease maraviroc daily when co-administered concentrations. with carbamazepine, phenobarbital or phenytoin in the absence of a potent CYP3A4 inhibitor. ANTIFUNGALS Ketoconazole 400 mg QD Maraviroc AUCtau: ↑ 5.00 CELSENTRI dose should be (maraviroc 100 mg BID) Maraviroc Cmax: ↑ 3.38 decreased to 150 mg twice Ketoconazole concentrations not daily when co-administered measured, no effect is expected. with ketoconazole. Itraconazole Not studied. Itraconazole, is a potent CELSENTRI dose should be CYP3A4 inhibitor and would be decreased to 150 mg twice expected to increase the exposure of daily when co-administered maraviroc. with itraconazole.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lopinavir (HOS-086269) atazanavir (HOS-086180) protease (HOS-085623) trimethoprim (HOS-085184) phenobarbital (HOS-085617) ketoconazole (HOS-084513) carbamazepine (HOS-085618) rifabutin (HOS-086262) etravirine (HOS-088088) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) clarithromycin (HOS-084517) efavirenz (HOS-087947) fosamprenavir (HOS-086182) ritonavir (HOS-084521) phenytoin (HOS-084531) tipranavir (HOS-086184)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-01-12T15:51:00Z · SHA-256 af7f0c7bbfd6e612d5a885c59ba9795f11ee85b00c3e0504de2a206af5fbec72 · Passage 1b627b7cd1e4efc3a8fc8f7680c5fda5526614bbd2d1f72d7ed1fca6f8314992 · Zeichen 13851–18833 im Abschnitt

Wechselwirkungen · Isentress

ISENTRESS 400 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6

HOS-119061 · Präparat HOS-094905

Given that raltegravir is metabolised primarily via UGT1A1, caution should be used when co-administering raltegravir with strong inducers of UGT1A1 (e.g., rifampicin). Rifampicin reduces plasma levels of raltegravir; the impact on the efficacy of raltegravir is unknown. However, if co-administration with rifampicin is unavoidable, a doubling of the dose of raltegravir can be considered in adults. There are no data to guide co-administration of raltegravir with rifampicin in patients below 18 years of age (see section 4.4). The impact of other strong inducers of drug metabolizing enzymes, such as phenytoin and phenobarbital, on UGT1A1 is unknown. Less potent inducers (e.g., efavirenz, nevirapine, etravirine, rifabutin, glucocorticoids, St. John's wort, pioglitazone) may be used with the recommended dose of raltegravir.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) rifabutin (HOS-086262) etravirine (HOS-088088) pioglitazone (HOS-089663) efavirenz (HOS-087947) nevirapine (HOS-088064) phenytoin (HOS-084531)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-11-17T13:16:00Z · SHA-256 6b95e5ffe7a0fcf11532bc18fa0933606a4dfe39d9d876e4b916acb6d89e55cc · Passage b8cec34ff635ec86f9cea3f144a77621f17aa513140b204ee827c2759a60c1f2 · Zeichen 1436–2265 im Abschnitt

Wechselwirkungen · Isentress

ISENTRESS 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 29

HOS-119137 · Präparat HOS-094905

Inducers of drug metabolizing enzymes The impact of medicinal products that are strong inducers of UGT1A1 such as rifampicin on raltegravir 1,200 mg once daily is unknown, but co-administration is likely to decrease raltegravir trough levels based on the reduction in trough concentrations observed with raltegravir 400 mg twice daily; therefore, co-administration with raltegravir 1,200 mg once daily is not recommended. The impact of other strong inducers of drug metabolizing enzymes, such as phenytoin and phenobarbital, on UGT1A1 is unknown; therefore, co-administration with raltegravir 1,200 mg once daily is not recommended. In drug interaction studies, efavirenz did not have a clinically meaningful effect on the pharmacokinetics of raltegravir 1,200 mg once daily; therefore, other less potent inducers (e.g., efavirenz, nevirapine, rifabutin, glucocorticoids, St. John's wort, pioglitazone) may be used with the recommended dose of raltegravir.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) rifabutin (HOS-086262) pioglitazone (HOS-089663) efavirenz (HOS-087947) nevirapine (HOS-088064) phenytoin (HOS-084531)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-11-17T13:16:00Z · SHA-256 6b95e5ffe7a0fcf11532bc18fa0933606a4dfe39d9d876e4b916acb6d89e55cc · Passage dd306f835043f6d85325974b1d31c99765ebfe8a587bfdee73dd9dba7ef89108 · Zeichen 2181–3137 im Abschnitt

Wechselwirkungen · Isentress

ISENTRESS 25 mg chewable tablets ISENTRESS 100 mg chewable tablets · Abschnitt 4.5 · PDF-Seite 55

HOS-119219 · Präparat HOS-094905

Given that raltegravir is metabolised primarily via UGT1A1, caution should be used when co-administering raltegravir with strong inducers of UGT1A1 (e.g., rifampicin). Rifampicin reduces plasma levels of raltegravir; the impact on the efficacy of raltegravir is unknown. However, if co-administration with rifampicin is unavoidable, a doubling of the dose of raltegravir can be considered in adults. There are no data to guide co-administration of raltegravir with rifampicin in patients below 18 years of age (see section 4.4). The impact of other strong inducers of drug metabolizing enzymes, such as phenytoin and phenobarbital, on UGT1A1 is unknown. Less potent inducers (e.g., efavirenz, nevirapine, etravirine, rifabutin, glucocorticoids, St. John's wort, pioglitazone) may be used with the recommended dose of raltegravir.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) rifabutin (HOS-086262) etravirine (HOS-088088) pioglitazone (HOS-089663) efavirenz (HOS-087947) nevirapine (HOS-088064) phenytoin (HOS-084531)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-11-17T13:16:00Z · SHA-256 6b95e5ffe7a0fcf11532bc18fa0933606a4dfe39d9d876e4b916acb6d89e55cc · Passage b8cec34ff635ec86f9cea3f144a77621f17aa513140b204ee827c2759a60c1f2 · Zeichen 1436–2265 im Abschnitt

Wechselwirkungen · Isentress

ISENTRESS 100 mg granules for oral suspension · Abschnitt 4.5 · PDF-Seite 79

HOS-119291 · Präparat HOS-094905

Given that raltegravir is metabolised primarily via UGT1A1, caution should be used when co-administering raltegravir with strong inducers of UGT1A1 (e.g., rifampicin). Rifampicin reduces plasma levels of raltegravir; the impact on the efficacy of raltegravir is unknown. However, if co-administration with rifampicin is unavoidable, a doubling of the dose of raltegravir can be considered in adults. There are no data to guide co-administration of raltegravir with rifampicin in patients below 18 years of age (see section 4.4). The impact of other strong inducers of drug metabolizing enzymes, such as phenytoin and phenobarbital, on UGT1A1 is unknown. Less potent inducers (e.g., efavirenz, nevirapine, etravirine, rifabutin, glucocorticoids, St. John's wort, pioglitazone) may be used with the recommended dose of raltegravir.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) rifabutin (HOS-086262) etravirine (HOS-088088) pioglitazone (HOS-089663) efavirenz (HOS-087947) nevirapine (HOS-088064) phenytoin (HOS-084531)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-11-17T13:16:00Z · SHA-256 6b95e5ffe7a0fcf11532bc18fa0933606a4dfe39d9d876e4b916acb6d89e55cc · Passage b8cec34ff635ec86f9cea3f144a77621f17aa513140b204ee827c2759a60c1f2 · Zeichen 1435–2264 im Abschnitt

Wechselwirkungen · Intelence

INTELENCE 25 mg tablets INTELENCE 100 mg tablets INTELENCE 200 mg tablets · Abschnitt 4.5 · PDF-Seite 11–12

HOS-119740 · Präparat HOS-095005

11 ANTIMALARIALS Artemether/ artemether Close monitoring of Lumefantrine AUC ↓ 0.62 (0.48-0.80) antimalarial response is 80/480 mg, 6 doses at 0, Cmin ↓ 0.82 (0.67-1.01) warranted when 8, 24, 36, 48, andCmax ↓ 0.72 (0.55-0.94) co-administering 60 hours dihydroartemisinin INTELENCE and AUC ↓ 0.85 (0.75-0.97) artemether/lumefantrine as a Cmin ↓ 0.83 (0.71-0.97) significant decrease in Cmax ↓ 0.84 (0.71-0.99) exposure of artemether and lumefantrine its active metabolite, AUC ↓ 0.87 (0.77-0.98) dihydroartemisinin, may Cmin ↔ 0.97 (0.83-1.15) result in decreased Cmax ↔ 1.07 (0.94-1.23) antimalarial efficacy. No etravirine dose adjustment is needed for AUC ↔ 1.10 (1.06-1.15) INTELENCE. Cmin ↔ 1.08 (1.04-1.14) Cmax ↔ 1.11 (1.06-1.17) ANTIMYCOBACTERIALS Rifampicin Not studied. Rifampicin and rifapentine are Combination not Rifapentine expected to decrease plasma concentrations of recommended. etravirine. INTELENCE should be used in combination with a boosted PI. Rifampicin is contraindicated in combination with boosted Pis. Rifabutin With an associated boosted PI: The combination of 300 mg once daily No interaction study has been performed. Based INTELENCE with a boosted on historical data, a decrease in etravirine PI and rifabutin should be exposure may be expected whereas an increase used with caution due to the in rifabutin exposure and especially in risk of decrease in etravirine 25-O-desacetyl-rifabutin may be expected. exposure and the risk of increase in rifabutin and With no associated boosted PI (out of the 25-O-desacetyl-rifabutin recommended indication for etravirine): exposures. rifabutin Close monitoring for AUC ↓ 0.83 (0.75-0.94) virologic response and for Cmin ↓ 0.76 (0.66-0.87) rifabutin related adverse Cmax ↓ 0.90 (0.78-1.03) reactions is recommended. 25-O-desacetyl-rifabutin Please refer to the product AUC ↓ 0.83 (0.74-0.92) information of the associated Cmin ↓ 0.78 (0.70-0.87) boosted PI for the dose Cmax ↓ 0.85 (0.72-1.00) adjustment of rifabutin to be etravirine used. AUC ↓ 0.63 (0.54-0.74) Cmin ↓ 0.65 (0.56-0.74) Cmax ↓ 0.63 (0.53-0.74) BENZODIAZEPINES Diazepam Not studied. Etravirine is expected to increase Alternatives to diazepam plasma concentrations of diazepam. should be considered. CORTICOSTEROIDS Dexamethasone Not studied. Dexamethasone is expected to Systemic dexamethasone (systemic) decrease plasma concentrations of etravirine should be used with caution or alternatives should be considered, particularly for chronic use.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lumefantrine (HOS-114826) artemether (HOS-116383) rifabutin (HOS-086262) diazepam (HOS-085904) dexamethasone (HOS-084535) rifapentine (HOS-116386)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-08-13T16:37:00Z · SHA-256 b6b2c3fd3d600c0f1fd17ddc8f6c1da50bcb8b2181089113d0397c5ec46864c4 · Passage 7e0fe54c45d58654b9841db8a2c7e820382e98227be81a55de584c6f746bd26a · Zeichen 20177–24856 im Abschnitt

Wechselwirkungen · Modigraf

Modigraf 0.2 mg granules for oral suspension Modigraf 1 mg granules for oral suspension · Abschnitt 4.5 · PDF-Seite 12–13

HOS-209770 · Präparat HOS-154375

12 Drug/Substance Class or Drug interaction effect Recommendations concerning co- Name administration dose may need to be adjusted gradually. Monitor graft function closely. Moderate CYP3A4 inducers: May decrease tacrolimus Monitor tacrolimus whole blood metamizole, phenobarbital, whole blood trough trough concentrations and isoniazid rifabutin, efavirenz, concentrations and increase increase tacrolimus dose if needed etravirine, nevirapine; weak the risk of rejection [see [see section 4.2]. CYP3A4 inducers: section 4.4]. Monitor graft function closely. flucloxacillin Caspofungin May decrease tacrolimus Monitor tacrolimus whole blood whole blood trough trough concentrations and concentrations and increase increase tacrolimus dose if needed the risk of rejection. [see section 4.2]. Monitor graft Mechanism of interaction has function closely. not been confirmed. Cannabidiol (P-gp inhibitor) There have been reports of Tacrolimus and cannabidiol increased tacrolimus blood should be co-administered with levels during concomitant caution, closely monitoring for use of tacrolimus with side effects. Monitor tacrolimus cannabidiol. This may be due whole blood trough to inhibition of intestinal P- concentrations and adjust the glycoprotein, leading to tacrolimus dose if needed [see increased bioavailability of sections 4.2 and 4.4]. tacrolimus. Products known to have high Tacrolimus is extensively Monitor tacrolimus whole blood affinity for plasma proteins, bound to plasma proteins. trough concentrations and adjust e.g.: NSAIDs, oral Possible interactions with tacrolimus dose if needed [see anticoagulants, oral other active substances section 4.2]. antidiabetics known to have high affinity for plasma proteins should be considered. Prokinetic agents: May increase tacrolimus Monitor tacrolimus whole blood metoclopramide, cimetidine whole blood trough trough concentrations and reduce and magnesium-aluminium- concentrations and increase tacrolimus dose if needed [see hydroxide the risk of serious adverse section 4.2]. reactions (e.g., neurotoxicity, Monitor closely for renal QT prolongation). function, for QT prolongation with ECG, and for other side effects. Maintenance doses of May decrease tacrolimus Monitor tacrolimus whole blood corticosteroids whole blood trough trough concentrations and concentrations and increase increase tacrolimus dose if needed the risk of rejection [see [see section 4.2]. section 4.4]. Monitor graft function closely. High dose prednisolone or May have impact on Monitor tacrolimus whole blood methylprednisolone tacrolimus blood levels trough concentrations and adjust (increase or decrease) when tacrolimus dose if needed. administered for the treatment of acute rejection.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prednisolone (HOS-086337) caspofungin (HOS-109306) phenobarbital (HOS-085617) cimetidine (HOS-085835) rifabutin (HOS-086262) methylprednisolone (HOS-088374) metoclopramide (HOS-090626) etravirine (HOS-088088) cannabidiol (HOS-090609) efavirenz (HOS-087947) nevirapine (HOS-088064) isoniazid (HOS-088590)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-03-03T17:00:00Z · SHA-256 1a464ac051c5783e49ce08a9d103d0d319997aa4add60584450928c1b11144a7 · Passage 0bb41e9b2822415bed45aeaa4baedfb69482463d056111334a789f729ecfd9cf · Zeichen 11046–15555 im Abschnitt

Wechselwirkungen · ellaOne

ellaOne 30 mg tablet · Abschnitt 4.5 · PDF-Seite 4

HOS-121383 · Präparat HOS-095343

Ulipristal acetate is metabolised by CYP3A4 in vitro. - CYP3A4 inducers In vivo results show that the administration of ulipristal acetate with a strong CYP3A4 inducer such as rifampicin markedly decreases Cmax and AUC of ulipristal acetate by 90% or more and decreases ulipristal acetate half-life by 2.2-fold corresponding to an approximately 10-fold decrease of ulipristal acetate exposure. Concomitant use of ellaOne with CYP3A4 inducers (e.g. barbiturates (including primidone and phenobarbital), phenytoin, fosphenytoin, carbamazepine, oxcarbazepine, herbal medicines containing Hypericum perforatum (St. John’s wort), rifampicin, rifabutin, griseofulvin, efavirenz and nevirapine) therefore reduces plasma concentrations of ulipristal acetate and may result in a decreased efficacy of ellaOne. For women who have used enzyme-inducing drugs in the past 4 weeks, ellaOne is not recommended (see section 4.4) and non-hormonal emergency contraception (i.e. a copper intrauterine device (Cu-IUD)) should be considered.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fosphenytoin (HOS-110222) phenobarbital (HOS-085617) carbamazepine (HOS-085618) rifabutin (HOS-086262) griseofulvin (HOS-091156) ulipristal acetate (HOS-121379) copper (HOS-112734) efavirenz (HOS-087947) nevirapine (HOS-088064) oxcarbazepine (HOS-110224) phenytoin (HOS-084531) primidone (HOS-090551)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-09-29T13:44:00Z · SHA-256 3bcc90490ab5bf0dd081a2d800bb02d498a50e916a38764a4f0fc343e4f5e8b6 · Passage 87464f734672865ea9df447f4532cd92447404847005d1bb51fb5ed63267d21a · Zeichen 69–1159 im Abschnitt

Wechselwirkungen · ellaOne

ellaOne 30 mg film-coated tablet · Abschnitt 4.5 · PDF-Seite 15

HOS-121411 · Präparat HOS-095343

Ulipristal acetate is metabolised by CYP3A4 in vitro. - CYP3A4 inducers In vivo results show that the administration of ulipristal acetate with a strong CYP3A4 inducer such as rifampicin markedly decreases Cmax and AUC of ulipristal acetate by 90% or more and decreases ulipristal acetate half-life by 2.2-fold corresponding to an approximately 10-fold decrease of ulipristal acetate exposure. Concomitant use of ellaOne with CYP3A4 inducers (e.g. barbiturates (including primidone and phenobarbital), phenytoin, fosphenytoin, carbamazepine, oxcarbazepine, herbal medicines containing Hypericum perforatum (St. John’s wort), rifampicin, rifabutin, griseofulvin, efavirenz and nevirapine) therefore reduces plasma concentrations of ulipristal acetate and may result in a decreased efficacy of ellaOne. For women who have used enzyme-inducing drugs in the past 4 weeks, ellaOne is not recommended (see section 4.4) and non-hormonal emergency contraception (i.e. a copper intrauterine device (Cu-IUD)) should be considered.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fosphenytoin (HOS-110222) phenobarbital (HOS-085617) carbamazepine (HOS-085618) rifabutin (HOS-086262) griseofulvin (HOS-091156) ulipristal acetate (HOS-121379) copper (HOS-112734) efavirenz (HOS-087947) nevirapine (HOS-088064) oxcarbazepine (HOS-110224) phenytoin (HOS-084531) primidone (HOS-090551)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-09-29T13:44:00Z · SHA-256 3bcc90490ab5bf0dd081a2d800bb02d498a50e916a38764a4f0fc343e4f5e8b6 · Passage 87464f734672865ea9df447f4532cd92447404847005d1bb51fb5ed63267d21a · Zeichen 69–1159 im Abschnitt

Wechselwirkungen · Zoely

Zoely 2.5 mg/1.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11–12

HOS-123116 · Präparat HOS-095645

Hepatic metabolism: Interactions can occur with substances that induce CYP450 enzymes, resulting in reduced concentrations of sex hormones and decreased effectiveness of combined oral contraceptives, including Zoely. These substances are represented mostly with anticonvulsants (e.g. carbamazepine, topiramate, phenytoin, phenobarbital, primidone, oxcarbazepine, felbamate); anti-infective drugs (e.g. rifampicin, rifabutin, griseofulvin); St. John’s wort; bosentan and HIV or Hepatitis C virus (HCV) protease inhibitors (e.g. ritonavir, boceprevir, telaprevir) and non-nucleoside reverse transcriptase inhibitors (e.g. efavirenz). Enzyme induction can occur after a few days of treatment. Maximal enzyme induction is generally 11 observed within a few weeks. After drug therapy is discontinued, enzyme induction can last for about 28 days.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): felbamate (HOS-110308) protease (HOS-085623) topiramate (HOS-110310) phenobarbital (HOS-085617) carbamazepine (HOS-085618) rifabutin (HOS-086262) hepatitis C virus (HOS-108813) telaprevir (HOS-090618) boceprevir (HOS-090617) griseofulvin (HOS-091156) efavirenz (HOS-087947) oxcarbazepine (HOS-110224) ritonavir (HOS-084521) bosentan (HOS-086291) phenytoin (HOS-084531) primidone (HOS-090551)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-02-19T01:25:00Z · SHA-256 dc49cf8021f816c4c7a796f72b78aa51d7e7cdb416565d60506c315b6ddcb3e2 · Passage f5dcfc8d38c2cd7a898cac819176553092ce45a5a5a7f2de510ba2c6181b7ca9 · Zeichen 330–1223 im Abschnitt

Wechselwirkungen · Jevtana

JEVTANA 60 mg concentrate and solvent for solution for infusion. · Abschnitt 4.5 · PDF-Seite 7

HOS-124035 · Präparat HOS-095771

CYP3A inducers Repeated administration of rifampin (600 mg once daily), a strong CYP3A inducer, resulted in an increase in cabazitaxel clearance of 21% corresponding to a decrease in AUC of 17%. Therefore concomitant administration of strong CYP3A inducers (e.g., phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital) should be avoided as a decrease of plasma concentrations of cabazitaxel may occur (see sections 4.2 and 4.4). In addition, patients should also refrain from taking St. John’s Wort.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifampin (HOS-088791) phenobarbital (HOS-085617) carbamazepine (HOS-085618) rifabutin (HOS-086262) phenytoin (HOS-084531)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-09-30T13:04:00Z · SHA-256 4c1eff0507207d5beb179217fec464186ac3bc1330fa052cff48922b617d3c37 · Passage 06be21692ce674b1ebeb289e96ecce71c922ee984f83017549e9237813b4c881 · Zeichen 791–1309 im Abschnitt

Wechselwirkungen · Plenadren

Plenadren 5 mg modified-release tablets Plenadren 20 mg modified-release tablets · Abschnitt 4.5 · PDF-Seite 5

HOS-213702 · Präparat HOS-155174

Potent CYP 3A4 inducers such as phenytoin, rifabutin, carbamazepine, barbiturates, rifampicin, St. John’s wort and less potent inducers such as the antiretroviral medicinal products efavirenz and nevirapine can enhance the metabolic clearance of cortisol, decrease terminal half-life and thus reduce circulating levels and increase fluctuations of cortisol (due to shorter terminal half-life). This may require dose adjustment of hydrocortisone.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): carbamazepine (HOS-085618) rifabutin (HOS-086262) efavirenz (HOS-087947) nevirapine (HOS-088064) phenytoin (HOS-084531)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2022-12-06T10:00:00Z · SHA-256 53473ee0edc582bcd44e3accf6dc87633e3875e631a072bc9c72cbe175c453a7 · Passage 3fa8fb10ebc49ec72e092b6798355379328d43234f6a858210238ba01306aab5 · Zeichen 105–550 im Abschnitt

Wechselwirkungen · Edurant

EDURANT 25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7

HOS-213947 · Präparat HOS-155234

(inhibition of CYP3A enzymes) ANTIMYCOBACTERIALS Rifabutin* rifabutin AUC ↔ Throughout co-administration of 300 mg once daily† rifabutin Cmin ↔ rilpivirine with rifabutin, the rilpivirine rifabutin Cmax ↔ dose should be increased from 25 mg 25-O-desacetyl-rifabutin AUC ↔ once daily to 50 mg once daily. When 25-O-desacetyl-rifabutin Cmin ↔ rifabutin co-administration is stopped, 25-O-desacetyl-rifabutin Cmax ↔ the rilpivirine dose should be decreased to 25 mg once daily. 300 mg once daily rilpivirine AUC ↓ 42% (+ 25 mg once daily rilpivirine Cmin ↓ 48% rilpivirine) rilpivirine Cmax ↓ 31%

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-04-11T14:54:00Z · SHA-256 c02ae8018d7111133de16dc7b25339ee095e696ed781b3973764a15d8d998fed · Passage 1f49a94689e6f85b76c75cb77d7ab90bdeb6a7549a85ec78c1d4d50c545b7c17 · Zeichen 8187–9179 im Abschnitt

Wechselwirkungen · Eviplera

Eviplera 200 mg/25 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8

HOS-214355 · Präparat HOS-155326

Eviplera should not be administered concomitantly with other medicinal products containing emtricitabine, tenofovir disoproxil or tenofovir alafenamide. Eviplera should not be administered concomitantly with rilpivirine hydrochloride unless needed for dose adjustment with rifabutin (see section 4.2).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir alafenamide (HOS-110476) rifabutin (HOS-086262)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-06-19T11:57:00Z · SHA-256 3873fd554f54608c25be65a5e155834d2d4981603221b5f24abb68e92e1af40e · Passage cbd035ee9d725e60ca2428bf451be94b355ea08ecb1ebc684712524ceb970a5f · Zeichen 997–1298 im Abschnitt

Wechselwirkungen · Eviplera

Eviplera 200 mg/25 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 15

HOS-214404 · Präparat HOS-155326

Fluconazole2 Rilpivirine: At a dose of 25 mg of rilpivirine, Itraconazole2 AUC: ↑ 49% no dose adjustment is required. Posaconazole2 Cmin: ↑ 76% Voriconazole2 Cmax: ↑ 30% Ketoconazole/Tenofovir disoproxil Interaction not studied. Antimycobacterials Rifabutin/Emtricitabine Interaction not studied. Co-administration is likely to Rifabutin (300 mg once daily)/ Rifabutin: cause significant decreases in Rilpivirine3 AUC: ↔ rilpivirine plasma concentrations Cmin: ↔ (induction of CYP3A enzymes). Cmax: ↔ When Eviplera is co-administered with rifabutin, an additional 25 mg 25-O-desacetyl-rifabutin: tablet of rilpivirine per day is AUC: ↔ recommended to be taken Cmin: ↔ concomitantly with Eviplera, for Cmax: ↔ the duration of the rifabutin co- administration. Rifabutin (300 mg once daily)/ Rilpivirine: Rilpivirine (25 mg once daily) AUC: ↓ 42% Cmin: ↓ 48% Cmax: ↓ 31%

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) rifabutin (HOS-086262)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-06-19T11:57:00Z · SHA-256 3873fd554f54608c25be65a5e155834d2d4981603221b5f24abb68e92e1af40e · Passage a0d342fe6d57e33e620cca251cfe8546adc6cc336b8d1b73d05beac4b318886d · Zeichen 20289–21955 im Abschnitt

Wechselwirkungen · Eviplera

Eviplera 200 mg/25 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 15

HOS-214405 · Präparat HOS-155326

Rifabutin (300 mg once daily)/ Rilpivirine: Rilpivirine (50 mg once daily) AUC: ↑ 16%* Cmin: ↔* Cmax: ↑ 43%* *compared to 25 mg once daily rilpivirine alone Rifabutin/Tenofovir disoproxil Interaction not studied.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-06-19T11:57:00Z · SHA-256 3873fd554f54608c25be65a5e155834d2d4981603221b5f24abb68e92e1af40e · Passage 3d15e60a3e2b02ec07ccfabff1b18d2d494ef9b8bc022e05a4eddf4d66c137ed · Zeichen 21957–22328 im Abschnitt

Wechselwirkungen · Duavive

DUAVIVE 0.45 mg/20 mg modified-release tablets · Abschnitt 4.5 · PDF-Seite 8

HOS-125222 · Präparat HOS-096029

The metabolism of oestrogens may be increased by concomitant use of substances known to induce drug-metabolising enzymes, such as anticonvulsants (e.g., phenobarbital, phenytoin, carbamazepine) and anti-infectives (e.g., rifampicin, rifabutin, nevirapine, efavirenz). Ritonavir and nelfinavir, although known as strong inhibitors, by contrast exhibit inducing properties when used concomitantly with steroid hormones. Herbal preparations containing St John’s wort (Hypericum perforatum) may induce the metabolism of oestrogens. Clinically, an increased metabolism of oestrogens may lead to decreased effect and changes in the uterine bleeding profile.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nelfinavir (HOS-084520) phenobarbital (HOS-085617) carbamazepine (HOS-085618) rifabutin (HOS-086262) lead (HOS-085592) efavirenz (HOS-087947) nevirapine (HOS-088064) ritonavir (HOS-084521) phenytoin (HOS-084531)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-11-06T02:00:00Z · SHA-256 cebc18aeeaa7e87d26ff41a36f1789bee3f7e1eaa839d2f6fdebebc62c1ef614 · Passage 4a99433b964f0cd0cd7d5317ff115a711319519a8c0c69338ef1236b324782c3 · Zeichen 660–1311 im Abschnitt

Wechselwirkungen · Zytiga

ZYTIGA 250 mg tablets · Abschnitt 4.5 · PDF-Seite 6

HOS-125278 · Präparat HOS-096037

Strong inducers of CYP3A4 (e.g., phenytoin, carbamazepine, rifampicin, rifabutin, rifapentine, phenobarbital, St John's wort [Hypericum perforatum]) during treatment are to be avoided, unless there is no therapeutic alternative.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) rifabutin (HOS-086262) rifapentine (HOS-116386) phenytoin (HOS-084531)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-10-18T14:31:00Z · SHA-256 1cd8edc18fae83339cc466c58b27be12ff13a584e8ad30419a21aea3ec2adf1f · Passage 9f070a595c2aa882f8aebe8a958bfbc9dc8f28f2bfb58eeb995e5b40ef010a1d · Zeichen 647–875 im Abschnitt

Quellenpassagen (163)

Wechselwirkungen · Tyverb

Wechselwirkungen · Celsentri

Wechselwirkungen · Celsentri

Wechselwirkungen · Isentress

Wechselwirkungen · Isentress

Wechselwirkungen · Isentress

Wechselwirkungen · Isentress

Wechselwirkungen · Intelence

Wechselwirkungen · Modigraf

Wechselwirkungen · ellaOne

Wechselwirkungen · ellaOne

Wechselwirkungen · Zoely

Wechselwirkungen · Jevtana

Wechselwirkungen · Plenadren

Wechselwirkungen · Edurant

Wechselwirkungen · Eviplera

Wechselwirkungen · Eviplera

Wechselwirkungen · Eviplera

Wechselwirkungen · Duavive

Wechselwirkungen · Zytiga